skip to main content

SciTech ConnectSciTech Connect

Title: The clinical impact of recent advances in LC-MS for cancer biomarker discovery and verification

Mass spectrometry-based proteomics has become an indispensable tool in biomedical research with broad applications ranging from fundamental biology, systems biology, and biomarker discovery. Recent advances in LC-MS have made it become a major technology in clinical applications, especially in cancer biomarker discovery and verification. To overcome the challenges associated with the analysis of clinical samples, such as extremely wide dynamic range of protein concentrations in biofluids and the need to perform high throughput and accurate quantification, significant efforts have been devoted to improve the overall performance of LC-MS bases clinical proteomics. In this review, we summarize the recent advances in LC-MS in the aspect of cancer biomarker discovery and quantification, and discuss its potentials, limitations, and future perspectives.
Authors:
; ; ; ; ; ; ; ;
Publication Date:
OSTI Identifier:
1243218
Report Number(s):
PNNL-SA-113659
Journal ID: ISSN 1478-9450; 48505; 400412000
DOE Contract Number:
AC05-76RL01830
Resource Type:
Journal Article
Resource Relation:
Journal Name: Expert Review of Proteomics; Journal Volume: 13; Journal Issue: 1
Publisher:
Taylor & Francis
Research Org:
Pacific Northwest National Laboratory (PNNL), Richland, WA (US), Environmental Molecular Sciences Laboratory (EMSL)
Sponsoring Org:
USDOE
Country of Publication:
United States
Language:
English
Subject:
Environmental Molecular Sciences Laboratory